JP2022049676A - Composition containing molecular hydrogen for preventing and/or improving chronic inflammation - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition for preventing and/or improving chronic inflammation.

SOLUTION: A composition for preventing and/or improving chronic inflammation, a disease associated with chronic inflammation, and a symptom associated with chronic inflammation in a subject including molecular hydrogen as an active ingredient. A disease caused by the chronic inflammation is a disease selected from the group consisting of cancer, obesity, diabetes mellitus, dyslipidemia, myocardial infarction, cerebral infarction, vestibular disease, hepatitis, cirrhosis, atopic dermatitis, asthma, rheumatoid arthritis, aging, dementia, Alzheimer disease, depression, ulcerative colitis, Crohn's disease, chronic obstructive airways disease, idiopathic pulmonary fibrosis, multiple sclerosis, pollinosis, and Parkinson disease.

SELECTED DRAWING: None

COPYRIGHT: (C)2022,JPO&INPIT

Description

The present invention provides a molecular hydrogen-containing composition for preventing and / or ameliorating chronic inflammation in a subject.

Inflammation includes chronic inflammation and acute inflammation. Although modern Western medicine can treat diseases caused by acute inflammation, treatment methods and suppression methods have been established for chronic inflammation, which is considered to be 80% of the causes of diseases, because the mechanism of chronic inflammation is not clear. do not have.
Chronic inflammation is a condition in which the inflammatory reaction (acute inflammation), which should be transient and subsided, is at a low level, but continues for a long period of time and becomes chronic. When the inflammatory state persists, abnormalities occur in the function and structure of living tissues and cause various diseases, but the mechanism of why the inflammation becomes chronic and becomes chronic inflammation is often unknown.
It is known that hydrogen, which is the active ingredient of the present invention, can eliminate hydroxyl radicals (Non-Patent Document 1). However, the therapeutic effect of hydrogen on chronic inflammation is unknown.
In addition, since hydrogen molecules are explosive at high concentrations, low concentrations of hydrogen below the explosive limit should be used for treatment and prevention. Not enough is known about it.

"Hydrogen molecules are pretty amazing" by Yu Fukai, Kobunsha New Book 2017

If chronic inflammation can be prevented and / or ameliorated, it will not only reduce patient distress and improve quality of life, but will also contribute to reducing medical costs. As mentioned above, little is known about the ingredients or substances that are useful in preventing and / or ameliorating chronic inflammation.
Under these circumstances, an object of the present invention is to prevent and / or ameliorate chronic inflammation by using relatively low concentrations of molecular hydrogen below the explosive limit, and / or symptoms associated with chronic inflammation. Is to promote the improvement of.

That is, the present invention includes the following features.
(1) A composition containing molecular hydrogen as an active ingredient for preventing and / or ameliorating chronic inflammation and symptoms associated with chronic inflammation in a subject.
(2) The composition according to (1), which is a liquid or gas containing the molecular hydrogen.
(3) The composition according to (2), wherein the liquid containing molecular hydrogen has a hydrogen concentration of 1 to 10 ppm.
(4) The composition according to (2), wherein the gas containing molecular hydrogen has a hydrogen concentration greater than zero (0) and a hydrogen concentration of 18.5% by volume or less.
(5) The composition according to any one of (1) to (4), wherein the subject is a mammal including a human.
(6) The composition containing the molecular hydrogen according to (1), (2), (4), and (5) as an active ingredient is prepared by using a mask, a cannula, or a room capable of supplying hydrogen. The composition according to any one of (1), (2), (4), and (5), which is inhaled by a subject.

The present invention is to provide a means for preventing and / or ameliorating chronic inflammation in a subject and efficiently supplying the subject with molecular hydrogen.

The present invention will be described in more detail.
1. 1. Composition for Preventing and / or Ameliorating Chronic Inflammation The present invention is a composition for preventing and / or ameliorating chronic inflammation and symptoms associated with chronic inflammation in a subject, which comprises molecular hydrogen as an active ingredient. I will provide a.
In the present specification, "chronic inflammation" refers to a state in which an inflammatory reaction that should originally be transiently subsided continues for a long period of time and becomes chronic, or an inflammatory substance or cell even though the tissue abnormality has been resolved. It refers to a state in which activities such as these do not converge, and include those caused by the breakdown of the immune system and inflammation of unknown cause. Clinically, a long term means at least one week or longer.
In the present specification, "acute inflammation" is clearly distinguished from chronic inflammation as inflammation having a different pathological condition, and when an abnormality occurs in a living body, in order to deal with the initial or minor abnormality. It refers to the reaction that occurs. Causes of acute inflammation include ischemia-reperfusion injury, side effects of drugs, burns, injuries, sprains, fractures, hair loss, infections with viruses and microorganisms, exposure to ultraviolet rays and radiation, smoking, strenuous exercise, etc. In animal experiments on rats and the like, inflammation model animals induced to be inflamed by a drug such as dextran sulfate are classified as acute inflammation.
As used herein, the term "disease caused by chronic inflammation" refers to cancer, obesity, diabetes, dyslipidemia, myocardial infarction, cerebral infarction, vestibular disease, hepatitis, liver cirrhosis, atopic dermatitis, asthma, rheumatoid arthritis, etc. Includes aging, dementia, Alzheimer's disease, depression, ulcerative colitis, Crohn's disease, chronic obstructive airway disease, idiopathic pulmonary fibrosis, multiple sclerosis, pollinosis, Parkinson's disease, etc.
As used herein, the term "symptoms associated with chronic inflammation" refers to symptoms associated with chronic inflammation. Such symptoms include, for example, redness, swelling, warmth, pain, difficulty walking, malaise, coughing, swelling, dyspnea, bleeding, diarrhea, bloody stools, abdominal pain, anemia, weight loss, twisted neck, The invention described herein also includes the development of polyps and insomnia, including the depressive symptoms associated with these symptoms, but asymptomatic chronic inflammation.
As used herein, the term "subject" includes mammals such as primates including humans, pet animals such as dogs and cats, and ornamental animals such as zoos. The preferred subject is a human.
In the present specification, "hydrogen" which is an active component of the composition of the present invention is molecular hydrogen (that is, gaseous hydrogen or hydrogen gas), and unless otherwise specified, it is simply referred to as "hydrogen" or "hydrogen gas". Refer to. In addition, the term "hydrogen" used in the present specification refers to H ₂ , D ₂ (deuterium), HD (hydrogen deuteride), or a mixed gas thereof in a molecular formula. Although D ₂ is expensive, it is known to have a stronger superoxide scavenging effect than H ₂ . The hydrogen that can be used in the present invention is H ₂ , D ₂ (deuterium), HD (hydrogen deuteride), or a mixed gas thereof, preferably H ₂ , or in place of or in place of H ₂ . D ₂ and / or HD may be used in admixture with H ₂ .
A preferred form of the composition of the present invention is a gas or liquid containing molecular hydrogen, preferably a gas containing molecular hydrogen.
The gas containing molecular hydrogen is preferably air containing hydrogen gas or a mixed gas containing hydrogen gas and oxygen gas. The concentration of hydrogen gas in the gas containing molecular hydrogen is greater than zero (0) and is 18.5% by volume or less, for example 0.5 to 18.5% by volume, preferably 1 to 10% by volume, for example. 2 to 8% by volume, 2 to 9% by volume, 2 to 10% by volume, 3 to 6% by volume, 3 to 7% by volume, 3 to 8% by volume, 3 to 9% by volume, 3 to 10% by volume, 4 to 5% by volume, 4-6% by volume, 4-7% by volume, 4-8% by volume, 4-9% by volume, 4-10% by volume, 5-8% by volume, 5-9% by volume, 5-10 By volume%, 6 to 7% by volume, 6 to 8% by volume, 6 to 9% by volume, 6 to 10% by volume, and the like. In the present invention, the higher the hydrogen gas concentration below the explosive limit, or the higher the daily hydrogen dose, the higher the effect of preventing or ameliorating the disease of humans or the animals tends to be.
Hydrogen is a flammable and explosive gas, and hydrogen gas with a hydrogen concentration of 18.5% or more is not only explosive but also detonates and should be avoided. Therefore, in preventing and / or ameliorating chronic inflammation, it is preferable to add hydrogen to the composition of the present invention and administer it to the subject under conditions that are safe for the subject such as humans.
When the gas other than hydrogen gas is air, the concentration of air is, for example, in the range of 81.5 to 99.5% by volume. When the gas other than hydrogen gas is a gas containing oxygen gas, the concentration of oxygen gas is, for example, in the range of 21 to 99.5% by volume. For example, nitrogen gas can be further contained as another main gas.
In a commentary paper published in the journal Medical Gas Research after the filing date of the present application, the inventor of the present application describes the amount of hydrogen gas inhaled by a subject to improve the disease by inhaling a large amount of hydrogen. "Therapies" are advocated. In the same paper, the inventor of the present application also claims that hydrogen scavenges hydroxyl radicals inside mitochondria and exhibits an anti-inflammatory effect. The "megahydrogen therapy" advocated by the inventor of the present application will realize a medical revolution that Linus Pauling could not achieve with "megavitamin therapy".
The liquid containing molecular hydrogen is specifically an aqueous liquid in which hydrogen gas is dissolved, and the aqueous liquid is not limited to, for example, water (for example, purified water, sterile water), physiological saline. , Buffer liquid (for example, buffer liquid having pH 4 to 7.4), drip liquid, infusion solution, injection solution, beverage (for example, tea beverage such as green tea and tea, fruit juice, green juice, vegetable juice, etc.). The hydrogen concentration of the liquid containing molecular hydrogen is not limited, for example, 1 to 10 ppm, preferably 1.2 to 9 ppm, for example, 1.5 to 9 ppm, 1.5 to 8 ppm, 1.5 to 7 ppm, 1. 5 to 6 ppm, 1.5 to 5 ppm, 1.5 to 4 ppm, 2 to 10 ppm, 2 to 9 ppm, 2 to 8 ppm, 2 to 7 ppm, 2 to 6 ppm, 2 to 5 ppm, 3 to 10 ppm, 3 to 9 ppm, 3 to 8 ppm, 3 to 7 ppm, 4 to 10 ppm, 4 to 9 ppm, 4 to 8 ppm, 4 to 7 ppm, 5 to 10 ppm, 5 to 9 ppm, 5 to 8 ppm, 5 to 7 ppm, and the like.
In the present invention, the higher the concentration of dissolved hydrogen below the explosive limit, or the higher the daily hydrogen dose, the greater the effect of preventing and / or ameliorating chronic inflammation tends to be.
The gas or liquid containing molecular hydrogen is blended so as to have a predetermined hydrogen gas concentration, and then, for example, a pressure-resistant container (for example, a stainless cylinder, an aluminum can, preferably the inside is laminated with an aluminum film). Filled in plastic bottles (eg pressure resistant PET bottles) and plastic bags, aluminum bags, etc. Aluminum has the property that it is difficult for hydrogen molecules to permeate. Alternatively, the gas containing molecular hydrogen or the liquid containing molecular hydrogen may be a hydrogen gas generator, a hydrogen water generator, or a hydrogen gas addition device, for example, a known or commercially available hydrogen gas supply device (molecular form) at the time of administration. For non-destructive addition of hydrogen gas to the inside of a bioapplicable liquid bag such as a drip solution), a hydrogen addition device (hydrogen water generation device), and a non-destructive hydrogen-containing device (for example, a device for generating a gas containing hydrogen). It may be manufactured on the spot using a device such as (device).
The hydrogen gas supply device mixes hydrogen gas generated by the reaction between a hydrogen generating agent (for example, metallic aluminum, magnesium hydride, etc.) and water with a diluting gas (for example, air, oxygen, etc.) at a predetermined ratio. (Japanese Patent No. 5228142, etc.). Alternatively, hydrogen gas generated by utilizing the electrolysis of water is mixed with a diluting gas such as oxygen and air (Japanese Patent No. 5502973, Japanese Patent No. 5900688, etc.). Thereby, for example, a gas containing molecular hydrogen having a hydrogen concentration in the range of 0.5 to 18.5% by volume can be prepared.
A hydrogen addition device is a device that generates hydrogen using a hydrogen generator and a pH adjuster and dissolves it in a biologically applicable liquid such as water (Japanese Patent No. 4756102, Japanese Patent No. 4652479, Japan). Japanese Patent No. 4950352, Japanese Patent No. 6159462, Japanese Patent No. 6170605, Japanese Patent Application Laid-Open No. 2017-104842, etc.). The combination of the hydrogen generator and the pH adjuster is, for example, metallic magnesium and a strongly acidic ion exchange resin or an organic acid (for example, malic acid, citric acid, etc.), metallic aluminum powder and calcium hydroxide powder, and the like. This makes it possible to prepare a liquid containing molecular hydrogen having a dissolved hydrogen concentration of, for example, about 1 to 10 ppm.
A non-destructive hydrogen-containing device is a device or instrument that adds hydrogen gas from the outside of a package to a commercially available bioapplicable solution such as a drip solution (for example, enclosed in a hydrogen permeable plastic bag such as a polyethylene bag). For example, it is commercially available from MiZ Co., Ltd. (http://www.e-mizu.co.jp/technology.html). This device can permeate hydrogen into the bag by immersing the bag containing the bioapplying liquid in saturated hydrogen water and dissolve hydrogen in the bioapplying liquid aseptically until the concentration equilibrium is reached. The device is composed of, for example, an electrolytic cell and a water tank, and water in the water tank can circulate between the electrolytic cell and the water tank to generate hydrogen by electrolysis. Alternatively, a simple disposable device can be used for the same purpose (Japanese Patent Laid-Open No. 2016-112562, etc.). This device contains a bioapplicable liquid-containing plastic bag (hydrogen permeable bag, for example, a polyethylene bag) and a hydrogen generator (eg, metallic calcium, metallic magnesium / cation exchange resin, etc.) in an aluminum bag. The hydrogen generating agent is wrapped in, for example, a non-woven fabric (for example, a water-permeable non-woven fabric). The hydrogen generated by wetting the hydrogen generator wrapped in the non-woven fabric with a small amount of water such as water vapor is non-destructively and aseptically dissolved in the bioapplicable liquid.
Alternatively, a purified hydrogen gas cylinder, a purified oxygen gas cylinder, or a purified air cylinder may be prepared, and a gas or liquid containing molecular hydrogen adjusted to have a predetermined hydrogen concentration, a predetermined oxygen or air concentration may be prepared.
Gases containing molecular hydrogen and liquids containing molecular hydrogen (eg, water (eg purified water, sterile water), saline, infusions, etc.) prepared using the above devices or instruments are chronically inflamed. Can be administered orally or parenterally to a subject of the drug before, during, or after surgery.
Another embodiment of the composition of the invention is a dosage form (eg, a tablet) containing a hydrogen generating agent that allows the generation of hydrogen in the gastrointestinal tract, which is prepared for oral administration (or ingestion) to a subject. , Capsules, etc.). The hydrogen generator is preferably composed of, for example, a food or an ingredient approved as a food additive.
As a method for administering the composition of the present invention to a subject, when molecular hydrogen is used as an active ingredient, for example, administration by inhalation, inhalation or the like, for example, transpulmonary administration is preferable, and a liquid containing molecular hydrogen is effective. When used as an ingredient, oral administration or intravenous administration (including infusion) is preferable. When inhaling gas, the gas is inhaled from the mouth or nose through a room that can supply hydrogen, such as a nasal cannula, a mask-type device that covers the mouth and nose, and a chamber, and sent to the lungs, and then to the whole body through blood. Can be delivered.
For liquids containing molecular hydrogen to be orally administered, a cooled liquid or a liquid stored at room temperature may be administered to the subject. It is known that hydrogen dissolves in water at a concentration of about 1.6 ppm (1.6 mg / L) under normal temperature and pressure, and the difference in solubility depending on the temperature is relatively small. Alternatively, when the liquid containing molecular hydrogen is in the form of a drip solution or an injection solution containing hydrogen gas prepared by using the above-mentioned non-destructive hydrogen-containing device, intravenous administration, intraarterial administration, etc. It may be administered to a subject by the parenteral route of administration.
A gas containing molecular hydrogen having a hydrogen concentration or a liquid containing molecular hydrogen having a dissolved hydrogen concentration once or multiple times (for example, 2 to 3 times) per day for a period of 1 week to 3 months or more. For example, it can be administered to a human for 1 week to 6 months or more (for example, 1 year or more, 2 years or more, etc.). When a gas containing molecular hydrogen is administered, it is preferable to inhale at least 30 minutes at a time. Since the longer the inhalation time is, the more effective the improvement is, for example, it can be administered over 30 minutes to 1 hour, 1 hour to 2 hours, 2 hours to 3 hours, or more. In addition, when gas containing molecular hydrogen is administered transpulmonary by inhalation or suction, it is under atmospheric pressure environment, or for example, it exceeds the standard atmospheric pressure (referred to as about 1.013 atmospheric pressure) and is 7.0 atmospheric pressure or less. High pressure within the range, for example 1.02 to 7.0 atm, preferably 1.02 to 5.0 atm, more preferably 1.02 to 4.0 atm, still more preferably 1.02 to 1.35 atm. The gas can be administered to the subject in a high pressure environment within the range (including a molecular hydrogen-containing gas).
2. 2. Methods for Preventing and / or Ameliorating Chronic Inflammation The present invention further comprises the above composition comprising molecular hydrogen as an active ingredient in a subject of chronic inflammation from surgical invasion and / or with surgery. Provide methods for promoting recovery or improvement from related symptoms.
The composition containing molecular hydrogen, chronic inflammation, symptoms related to chronic inflammation, dosage, administration method, etc. are described in 1. above. As explained in.
In the method of the present invention, the subject is subjected to greater than zero (0) and less than or equal to 18.5% by volume, for example 0.5 to 18.5% by volume, 2 to 10% by volume, 2 to 9% by volume, 2 to. 8% by volume, 3-10% by volume, 3-9% by volume, 3-8% by volume, 3-7% by volume, 3-6% by volume, 4-10% by volume, 4-9% by volume, 4-8% by volume. % 4-7% by volume, 4-6% by volume, 4-5% by volume, 5-10% by volume, 5-9% by volume, 5-8% by volume, 6-10% by volume, 6-9% by volume, 6-8% by volume, 6-7% by volume, preferably 5-10% by volume, 5-8% by volume, for example 6-10% by volume, 6-8% by volume, 6-7% by volume, etc. A hydrogen-containing gas (preferably air or oxygen) is inhaled or inhaled per day for, for example, 1-3 hours or more, eg, 1-3 months or more, 4-7 months or more, It can be continued for 1 to 3 years or more.
Alternatively, in the method of the present invention, the subject is subjected to, for example, 1 to 10 ppm, 1.5 to 9 ppm, 1.5 to 8 ppm, 1.5 to 7 ppm, 1.5 to 6 ppm, 1.5 to 5 ppm, 1.5. ~ 4ppm, 2 ~ 10ppm, 2 ~ 9ppm, 2 ~ 8ppm, 2 ~ 7ppm, 2 ~ 6ppm, 2 ~ 5ppm, 3 ~ 10ppm, 3 ~ 9ppm, 3 ~ 8ppm, 3 ~ 7ppm, 4 ~ 10ppm, 4 ~ 9ppm 4, 8 ppm, 4 to 7 ppm, 5 to 10 ppm, 5 to 9 ppm, 5 to 8 ppm, 5 to 7 ppm, etc., preferably 3 to 10 ppm, 4 to 10 ppm, 5 to 10 ppm, 5 to 9 ppm, 5 to 8 ppm, 5 to A molecular hydrogen-containing liquid such as 7 ppm is administered, for example, 200 to 500 mL per intravenous administration, and 500 to 1000 mL per dose for oral administration, for example, 0.5 to 3 months or the like. It can be continued for 4 to 7 months or more, 1 to 3 years or more.
The method of the present invention may further be combined with a therapeutic agent used for the treatment of chronic inflammation, if necessary. When used in combination, it is expected to prevent and / or improve chronic inflammation.

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

<Case of chronic inflammation due to hydrogen inhalation>
A 13-year-old Miniature Schnauzer had a right-handed twist, but symptoms disappeared over time. However, four months later, the symptoms of right-handed torticollis and difficulty in standing again appeared, and the movement of sliding the legs on the flooring became conspicuous. Usually, idiopathic vestibular disease, if idiopathic (acute), tends to stabilize in a few days and gradually recover in a few weeks, but Miniature Schnauzer shows improvement even after follow-up. I couldn't. Veterinarians diagnosed that neurological examination resulted in chronic inflammation due to cerebellar infarction, resulting in symptoms of idiopathic vestibular syndrome. In addition to Chinese herbs, treatment with vitamin C and other vitamins with antioxidant activity did not improve the symptoms caused by chronic inflammation. Therefore, it was considered that the cause of chronic inflammation of Miniature Schnauzer was caused by something other than oxidative stress. The owner, who was pessimistic about the lack of improvement in his symptoms, requested euthanasia. Prior to euthanasia, veterinarians proposed and implemented hydrogen gas inhalation therapy. Miniature Schnauzer in a chamber introduced with hydrogen gas generated from a hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type MHG2000-α, hydrogen concentration about 6.0 to 7.0%, hydrogen gas generation amount about 120 ml / min) Was bred for 24 hours a day. The Miniature Schnauzer was able to stand up on the 5th day after the start of breeding in the hydrogen-introduced chamber. He was discharged on the 8th day because his findings of chronic inflammation had improved. After that, follow-up was performed at home, but the right-handed torticollis gradually improved, and two months after discharge, no signs of chronic inflammation were observed, and the animal recovered to the point where it was able to run. Doctors diagnosed that the suppression of chronic inflammation by inhaling hydrogen gas improved the idiopathic precondition.

<Case of chronic inflammation due to hydrogen inhalation>
Chihuahuas with high LDL cholesterol levels and cerebellar infarction caused by chronic inflammation in the brain were treated with antioxidants, but no improvement was seen. At the suggestion of a veterinarian, a nasal cannula for dogs was used with a hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-α, hydrogen concentration of about 4.0 to 5.0%, hydrogen gas generation amount of about 200 ml / min). When hydrogen was inhaled for 12 hours a day, he was able to stand up on the 8th day and was able to walk on the 14th day and was discharged from the hospital. A similar effect was confirmed in one other dog.

<Case 3 of chronic inflammation due to hydrogen inhalation>
A vitamin preparation having an antioxidant effect was administered to cats with chronic kidney disease caused by chronic kidney inflammation with high urea nitrogen and creatinine levels, but no improvement was observed. Hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-mini, hydrogen concentration about 1.0 to 2.0%, hydrogen gas generation amount about 30 ml / min) Hydrogen gas inhalation was performed 24 hours a day for 7 days. However, the creatinine level improved. After another week of inhalation, he was able to be discharged from the hospital. After discharge, a saline solution containing 1.0 ppm of hydrogen was infused every 1 or 2 days, and the urea nitrogen and creatinine levels returned to normal. It was also confirmed that the swelling of the kidney was reduced and the inflammation was improved.

<Case 4 of chronic inflammation due to hydrogen inhalation>
Hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-α, hydrogen concentration approx. 4.0-5.0%, hydrogen gas generation amount approx. 200 ml / min) for dogs with liver failure caused by chronic hepatitis. When hydrogen gas was inhaled for 24 hours a day for 14 days, the hepatitis marker decreased.

<Case 5 of chronic inflammation due to hydrogen inhalation>
Swelling caused by chronic inflammation caused by dog cancer is caused by a hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-α, hydrogen concentration about 4.0 to 5.0%, hydrogen gas generation amount about 200 ml / min). After inhaling hydrogen gas (6 hours a day for 12 days), swelling developed, appetite returned, and QOL improved.

<Case 6 of chronic inflammation due to hydrogen inhalation>
For dogs with chronic inflammation of the heart caused by arteriosclerosis and heart failure due to mitral valve insufficiency, a hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-α, hydrogen concentration approx. 4.0-5.0%, hydrogen) When hydrogen gas was inhaled for 24 hours a day for 14 days using a gas generation amount of about 200 ml / min), chronic inflammation was alleviated, and the patient recovered to the point where he could be discharged without surgery.

Patients diagnosed with Parkinson's disease had a blood test that showed a CRP (C-reactive protein) level of 1.5 mg / dL, which is an inflammation marker, exceeding the standard value (October 23, 2020). The normal value of CRP is 0.0 to 0.4 mg / dL. From October 24, inhalation for 3 hours a day using a hydrogen gas inhaler manufactured by MiZ Co., Ltd. (type Jobs-α, hydrogen concentration about 4.0 to 5.0%, hydrogen gas generation amount about 200 ml / min) The CRP value dropped to 0.2 mg / dL in the blood test on November 2, the same year.

INDUSTRIAL APPLICABILITY According to the present invention, chronic inflammation can be prevented and / or ameliorated by administering a composition containing molecular hydrogen.

Claims (8)

A composition comprising molecular hydrogen as an active ingredient for preventing and / or ameliorating chronic inflammation, diseases associated with chronic inflammation, and symptoms associated with chronic inflammation in a subject. Diseases caused by the chronic inflammation include cancer, obesity, diabetes, dyslipidemia, myocardial infarction, cerebral infarction, vestibular disease, hepatitis, liver cirrhosis, atopic dermatitis, asthma, rheumatoid arthritis, aging, dementia, Alzheimer's disease. Characterized by being selected from the group consisting of disease, depression, ulcerative colitis, Crohn's disease, chronic obstructive airway disease, idiopathic pulmonary fibrosis, multiple sclerosis, pollinosis, and Parkinson's disease. The composition according to claim 1. Symptoms associated with the chronic inflammation include redness, swelling, warmth, pain, difficulty walking, malaise, coughing, squeezing, dyspnea, bleeding, diarrhea, bloody stools, abdominal pain, anemia, weight loss, twisted neck, The composition according to claim 1, wherein the composition is selected from the group consisting of the development of polyps, insomnia, and depressive symptoms associated with these symptoms. The composition according to any one of claims 1 to 3, which is a liquid or a gas containing the molecular hydrogen. The composition according to claim 4, wherein the liquid containing molecular hydrogen has a hydrogen concentration of 1 to 10 ppm. The composition according to claim 4, wherein the gas containing molecular hydrogen has a hydrogen concentration greater than zero (0) and a hydrogen concentration of 18.5% by volume or less. The composition according to any one of claims 1 to 6, wherein the subject is a mammal including a human. The composition comprising the molecular hydrogen according to claims 1, 2, 4, and 5 as an active ingredient is inhaled by a subject using a mask, a cannula, or a room capable of supplying hydrogen. The composition according to any one of claims 1 to 4, 6 and 7.